What is the value of growth hormone therapy in Prader Willi syndrome?

Archives of Disease in Childhood

Volumn 99, Issue 2, 2014, Pages 166-170

  Bridges, Nicola ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ABDOMINAL OBESITY; ADULTHOOD; BIRTH WEIGHT; BODY COMPOSITION; BODY HEIGHT; CALORIC INTAKE; CHILD DEVELOPMENT; CHILDHOOD; CHROMOSOME 15; CLINICAL FEATURE; COGNITION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DRUG MONITORING; DRUG SAFETY; ENVIRONMENTAL FACTOR; EXERCISE; FAT MASS; FEEDING BEHAVIOR; FOOD INTAKE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; HYPERPHAGIA; HYPOTHYROIDISM; LEAN BODY WEIGHT; LUNG FUNCTION TEST; LYMPHOID TISSUE; MORBID OBESITY; MUSCLE HYPOTONIA; MUSCLE MASS; NEWBORN PERIOD; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; SCOLIOSIS; TREATMENT OUTCOME; WEIGHT GAIN;

GROWTH HORMONE; HYPERPHAGIA; OBESITY; PRADER WILLI SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMAN GROWTH HORMONE; HUMANS; INFANT; OBESITY; PRADER-WILLI SYNDROME; YOUNG ADULT;

EID: 84892801767     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303760     Document Type: Review

References (37)

1. Whittington JE, Butler JV, Holland AJ. Changing rates of genetic subtypes of Prader-Willi syndrome in the UK. Eur J Hum Genet 2007;15:127-30.
2. Goldstone AP, Holland AJ, Hauffa BP, et al.; on behalf of speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97.
3. Copet P, Jauregi J, Laurier V, et al. Cognitive profile in a large French cohort of adults with Prader-Willi syndrome: differences between genotypes. J Intellect Disabil Res 2010;54:204-15.
4. Whittington J, Holland A, Webb T, et al. Cognitive abilities and genotype in a population-based sample of people with Prader-Willi syndrome. J Intellect Disabil Res 2004;48(Pt 2):172-87.
5. Eiholzer U, Stutz K, Weinmann C, et al. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998;157:890-3.
6. Oto Y, Obata K, Matsubara K, et al. Growth hormone secretion and its effect on height in pediatric patients with different genotypes of Prader-Willi syndrome. Am J Med Genet 2012;158A:1477-80.
7. Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet 2011;155A:1040-9.
8. Butler JV, Whittington JE, Holland AJ, et al. The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood. Dev Med Child Neurol. 2010;52:506-7.
9. Butler MG, Sturich J, Lee J, et al. Growth standards of infants with Prader-Willi syndrome. Pediatrics 2011;127:687-95.
10. Wollmann HA, Schultz U, Grauer ML, et al. Reference values for height and weight in Prader Willi syndrome based on 315 patients. Eur J Pediatr 1998;157:634-42.
11. Eiholzer U, l'Allemand D, Rousson V, et al . Hypothalamic and Gonadal Components of Hypogonadism in Boys with Prader-Labhart- Willi Syndrome. J Clin Endocrinol Metab 2006;91:892-8.
12. Whittington JE, Holland AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792-8.
13. Sinnema M, Schrander-Stumpel CTRM, Maaskant MA, et al. Aging in Prader-Willi syndrome: twelve persons over the age of 50 years. Am J Med Genet 2012;158A:1326-36.
14. de Lind van Wijngaarden RFA, Siemensma EPC, Festen DAM, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009;94:4205-15.
15. Angulo MA, Castro-Magana M, Lamerson M, et al. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet 2007;143A:1456-61.
16. Carrel AL, Myers SE, Whitman BY, et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-willi syndrome. J Clin Endocrinol Metab 2010;95:1131-6.
17. Deal CL, Tony M, Höybye C, et al. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87.
18. Festen DAM, de Lind van Wijngaarden R, van Eekelen M, et al. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008;69:443-51.
19. Sipilä I, Sintonen H, Hietanen H, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatr 2010;99:1712-18.
20. Coupaye M, Lorenzini F, Lloret-Linares C, et al. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab 2013;98:E328-35.
21. Reus L, van Vlimmeren LA, Staal JB, et al. The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: A systematic review. Neurosci Biobehav Rev 2012;36:1817-38.
22. Festen DAM, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008;68:919-25.
23. Myers SE, Whitman BY, Carrel AL, et al. Two years of growth hormone therapy in young children with Prader- Willi syndrome: Physical and neurodevelopmental benefits. Am. J. Med. Genet. [Internet] . 2007;143A:443-8.
24. Siemensma EPC, Tummers-de Lind van Wijngaarden RFA, Festen DAM, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 2012;97:2307-14.
25. Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf) 2012;77:86-93.
26. Sode-Carlsen R, Farholt S, Rabben KF, et al. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine 2012;41:191-9.
27. Fillion M, Deal C, Van Vliet G. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome. J Pediatr 2009;154:230-1.
28. Tauber M, Diene G, Molinas C, et al. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet 2008;146A:881-7.
29. Williams K, Scheimann A, Sutton V, et al. Sleepiness and sleep disordered breathing in Prader-Willi syndrome: relationship to genotype, growth hormone therapy, and body composition. J Clin Sleep Med 2008;4:111-18.
30. Nixon GM, Rodda CP, Davey MJ. Longitudinal association between growth hormone therapy and obstructive sleep apnea in a child with Prader-Willi syndrome. J Clin Endocrinol Metab 2011;96:29-33.
31. Al-Saleh S, Al-Naimi A, Hamilton J, et al. Longitudinal Evaluation of Sleep-Disordered Breathing in Children with Prader-Willi Syndrome during 2 Years of Growth Hormone Therapy. J Pediatr 2013;162:263-8.
32. Festen DAM, de Weerd AW, van den Bossche RAS, et al. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2006;91:4911-15.
33. de Lind van Wijngaarden RFA, de Klerk LWL, Festen DAM, et al. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94:1274-80.
34. Crino A, Di Giorgio G, et al. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res 2007;68:83-90.
35. Feigerlová E, Diene G, Oliver I, et al. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. J Clin Endocrinol Metab 2010;95:4600-8.
36. NICE. Human growth hormone (somatropin) in adults with growth hormone deficiency. (TA64). National Institute for Care Excellence, 2007.
37. NICE. Human growth hormone (somatropin) for the treatment of growth failure in children. (TA188). National Institute for Care Excellence, 2010.